First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.

Satouchi M, Nosaki K, Takahashi T, Nakagawa K, Aoe K, Kurata T, Sekine A, Horiike A, Fukuhara T, Sugawara S, Umemura S, Saka H, Okamoto I, Yamamoto N, Sakai H, Kishi K, Katakami N, Horinouchi H, Hida T, Okamoto H, Atagi S, Ohira T, Han SR, Noguchi K, Ebiana V, Hotta K

Open source

DOI: 10.1111/cas.14647
Published: 2020 Dec
Container: Cancer science
Publisher: Not recorded
Open access: yes

Credibility signals

serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/cas.14647,
  title = {First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.},
  author = {Satouchi M and Nosaki K and Takahashi T and Nakagawa K and Aoe K and Kurata T and Sekine A and Horiike A and Fukuhara T and Sugawara S and Umemura S and Saka H and Okamoto I and Yamamoto N and Sakai H and Kishi K and Katakami N and Horinouchi H and Hida T and Okamoto H and Atagi S and Ohira T and Han SR and Noguchi K and Ebiana V and Hotta K},
  year = {2020},
  journal = {Cancer science},
  doi = {10.1111/cas.14647},
  url = {https://doi.org/10.1111/cas.14647}
}

RIS

TY  - JOUR
TI  - First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
AU  - Satouchi M
AU  - Nosaki K
AU  - Takahashi T
AU  - Nakagawa K
AU  - Aoe K
AU  - Kurata T
AU  - Sekine A
AU  - Horiike A
AU  - Fukuhara T
AU  - Sugawara S
AU  - Umemura S
AU  - Saka H
AU  - Okamoto I
AU  - Yamamoto N
AU  - Sakai H
AU  - Kishi K
AU  - Katakami N
AU  - Horinouchi H
AU  - Hida T
AU  - Okamoto H
AU  - Atagi S
AU  - Ohira T
AU  - Han SR
AU  - Noguchi K
AU  - Ebiana V
AU  - Hotta K
PY  - 2020
JO  - Cancer science
DO  - 10.1111/cas.14647
UR  - https://doi.org/10.1111/cas.14647
ER  -

APA

M, S., K, N., T, T., K, N., K, A., T, K., A, S., A, H., T, F., S, S., S, U., H, S., I, O., N, Y., H, S., K, K., N, K., H, H., T, H., H, O., S, A., T, O., SR, H., K, N., V, E., & K, H. (2020). First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.. Cancer science. https://doi.org/10.1111/cas.14647

Source records

pubmed · retrieved 2026-09-24T18:31:21.196Z